Trials / Active Not Recruiting
Active Not RecruitingNCT02775227
HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
HYPAR Trial - Hydrocortisone vs Pasireotide in Reducing Pancreatic Fistula and Other Complications After Pancreatic Resection - a Prospective, Randomized, Controlled Trial
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Helsinki University Central Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pancreatic resections carry a high risk for complications, especially pancreatic fistula. Both hydrocortisone and pasireotide have been shown to be effective in reducing complications in earlier RCTs. The aim of this study is to compare the effectiveness and safety of these two drugs in preventing complications of pancreatic surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydrocortisone | |
| DRUG | Pasireotide |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2019-01-01
- Completion
- 2029-12-01
- First posted
- 2016-05-17
- Last updated
- 2020-08-24
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT02775227. Inclusion in this directory is not an endorsement.